The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Dompe Farmaceutici sales in the US from 2017 to 2023, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Dompe Farmaceutici SpA, United States Revenue

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Dompe Farmaceutici SpA (Dompe) is a biopharmaceutical company that includes research and development of innovative solutions. The company product pipeline includes NGF which targets neurotrophic keratitis, glaucoma; TRPLM2 inhibitor targets AKC (atopic keratoconjunctivitis); Reparixin for CAP (community aquired pneumonia), ARDS (acute respiratory distress syndrome); Ladarixin which targets type 1 diabetes. Dompe offers its product in therapeutic areas such as pain and anti-inflammatory, neurotrophic keratitis, cough and cold, eye, skin, oral care, cardiovascular and gastro. The company has operations in the US and China. Dompe is headquartered in Milan, Italy. Key subsidiaries of Dompe Farmaceutici include Dompe, Anabasis and Dompe Biotec.

The key metrics of Dompe Farmaceutici related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2023 are shown below:

As Dompe Farmaceutici is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Dompe Farmaceutici.

For a detailed understanding of the performance of Dompe Farmaceutici, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.